Members |
targetComponentId |
N2: Bilateral metastasis in lymph node(s) > 6 cm in greatest dimension, above supraclavicular fossa |
American Joint Committee on Cancer cN2 (qualifier value) |
N2: Metastasis in 4 or more lymph nodes |
American Joint Committee on Cancer cN2 (qualifier value) |
N2: Metastasis in 7-15 perigastric lymph nodes |
American Joint Committee on Cancer cN2 (qualifier value) |
N2: Metastasis in a single ipsilat lymph node >3cm but <6cm in greatest dimension; or in multiple ipsilat lymph nodes, none >6cm in greatest dimension; or in bilat or contralat lymph nodes, none >6cm in greatest dimension |
American Joint Committee on Cancer cN2 (qualifier value) |
N2: Metastasis in a single lymph node, > 2 cm but <= 5 cm in greatest dimension, or multiple lymph nodes, none > 5 cm in greatest dimension |
American Joint Committee on Cancer cN2 (qualifier value) |
N2: Metastasis in ipsilateral mediastinal and/or subcarinal lymph node(s) |
American Joint Committee on Cancer cN2 (qualifier value) |
N2: Metastasis in more than one regional lymph node |
American Joint Committee on Cancer cN2 (qualifier value) |
N2: Metastasis to ipsilateral axillary lymph node(s) fixed to one another or to other structures |
American Joint Committee on Cancer cN2 (qualifier value) |
N2: Metastasis to unilateral internal iliac and/or inguinal lymph node(s) |
American Joint Committee on Cancer cN2 (qualifier value) |
N2: Metastasis with a lymph node mass >2 cm but <= 5 cm in greatest dimension, or more than 5 nodes positive, none > 5 cm; or evidence of extranodal extension of tumor |
American Joint Committee on Cancer cN2 (qualifier value) |
N2a: Metastasis in a single ipsilateral lymph node, > 3 cm but < 6 cm in greatest dimension |
American Joint Committee on Cancer cN2a (qualifier value) |
N2b: Metastasis in multiple ipsilateral lymph nodes, none > 6 cm in greatest dimension |
American Joint Committee on Cancer cN2b (qualifier value) |
N2c: Metastasis in bilateral or contralateral lymph nodes, none > 6 cm in greatest dimension |
American Joint Committee on Cancer cN2c (qualifier value) |
N3 category |
American Joint Committee on Cancer cN3 (qualifier value) |
N3: Metastasis in >15 perigastric lymph nodes |
American Joint Committee on Cancer cN3 (qualifier value) |
N3: Metastasis in a lymph node > 5 cm in greatest dimension |
American Joint Committee on Cancer cN3 (qualifier value) |
N3: Metastasis in a lymph node > 6 cm in greatest dimension |
American Joint Committee on Cancer cN3 (qualifier value) |
N3: Metastasis in contralateral mediastinal, contralateral hilar, ipsilateral or contralateral scalene or supraclavicular lymph node(s) |
American Joint Committee on Cancer cN3 (qualifier value) |
N3: Metastasis in lymph node(s) |
American Joint Committee on Cancer cN3 (qualifier value) |
N3: Metastasis to ipsilateral internal mammary lymph node(s) |
American Joint Committee on Cancer cN3 (qualifier value) |
N3: Metastasis with a lymph node mass > 5 cm in greatest dimension |
American Joint Committee on Cancer cN3 (qualifier value) |
N3a: > 6 cm in dimension |
American Joint Committee on Cancer cN3a (qualifier value) |
N3b: extension to supraclavicular fossa |
American Joint Committee on Cancer cN3b (qualifier value) |
NAD(P)H dehydrogenase (FMN) |
Reduced nicotinamide adenine dinucleotide (phosphate) dehydrogenase (quinone) (substance) |
NX category |
American Joint Committee on Cancer cNX (qualifier value) |
Nabothian follicles on cervix |
Mucous retention cyst of cervix uteri (disorder) |
Nabothian follicles on cervix |
Mucous retention cyst of cervix uteri (disorder) |
Nabothian follicles on cervix |
Mucous retention cyst of cervix uteri (disorder) |
Nabumetone 500mg dispersible tablet |
Nabumetone 2.5 mg/mL oral solution |
Nail dystrophy resulting from poisonous chemical |
Nail dystrophy caused by chemical |
Nail flap |
Flap (substance) |
Nairobi sheep disease serogroup |
Nairobi sheep disease virus (organism) |
Nape of neck flap |
Flap (substance) |
Naphazoline hydrochloride + polyvinyl alcohol + zinc sulfate 0.02%wv/0.25%wv/0.25%wv drops |
Product containing only naphazoline and polyvinyl alcohol and zinc sulfate (medicinal product) |
Naproxen 200mg/pseudoephedrine 120mg m/r tablet |
Product containing only naproxen and pseudoephedrine (medicinal product) |
Naproxen 200mg/pseudoephedrine 120mg prolonged-release oral tablet |
Product containing only naproxen and pseudoephedrine (medicinal product) |
Naproxen 500mg m/r tablet |
Product containing precisely naproxen 500 milligram/1 each gastro-resistant oral tablet (clinical drug) |
Naproxen sodium 220mg/pseudoephedrine 120mg m/r tablet |
Product containing only naproxen and pseudoephedrine (medicinal product) |
Naproxen sodium 220mg/pseudoephedrine 120mg prolonged-release oral tablet |
Product containing only naproxen and pseudoephedrine (medicinal product) |
Naproxen sodium 375mg gastro-resistant oral tablet |
Product containing precisely naproxen 375 milligram/1 each gastro-resistant oral tablet (clinical drug) |
Naproxen sodium 375mg m/r tablet |
Product containing precisely naproxen 375 milligram/1 each gastro-resistant oral tablet (clinical drug) |
Naproxen sodium 500mg gastro-resistant oral tablet |
Naproxen only product in oral dose form |
Naproxen sodium 500mg m/r tablet |
Naproxen only product in oral dose form |
Narrow open angle |
Narrow angle (finding) |
Nasal cavity and ethmoid sinus TNM finding |
American Joint Committee on Cancer allowable value |
Nasal diagnostic laryngoscopy |
Nasal laryngoscopy |
Nasal flap |
Flap (substance) |
Nasal sinus operations NOS |
Operation on accessory sinus |
Nasal sinus operations NOS |
Operation on accessory sinus |
Nasal sinusectomy - other |
Accessory sinus excision (procedure) |
Nasal sinusectomy - other |
Accessory sinus excision (procedure) |
Nasal sinusotomy - other |
Operation on accessory sinus |
Nasal sinusotomy - other |
Operation on accessory sinus |
Nasalis flap |
Flap (substance) |
Nasolabial flap |
Flap (substance) |
Nasopharyngoscopy: [diagnostic NEC] or [NEC] |
Nasopharyngoscopy |
Nasopharynx TNM finding |
American Joint Committee on Cancer allowable value |
National gov't. officer NOS |
National government officer (occupation) |
National government general administrator NOS |
Government administrator |
National government general administrator NOS |
Government administrator |
National government officer NOS |
National government officer (occupation) |
Natural scientist NOS |
Natural scientist |
Natural scientist NOS |
Natural scientist |
Nausea |
Nausea (finding) |
Nausea NOS |
Nausea (finding) |
Nausea NOS |
Nausea (finding) |
Near complete invasion of mesorectum by tumor |
Mesorectal specimen nearly completely intact (finding) |
Neck disorder NOS |
Disorder of neck (disorder) |
Neck disorder NOS |
Disorder of neck (disorder) |
Neck lymphangiogram |
Fluoroscopic lymphangiography of neck with contrast (procedure) |
Neck lymphangiogram |
Fluoroscopic lymphangiography of neck with contrast (procedure) |
Neck of other metacarpal |
Neck of metacarpal bone structure (body structure) |
Neck soft tissue X-ray |
Plain X-ray of soft tissue of neck (procedure) |
Neck soft tissue X-ray |
Plain X-ray of soft tissue of neck (procedure) |
Neer 2 part fracture |
Neer two-part fracture |
Neer 3 part fracture |
Neer three-part fracture |
Neer 4 part fracture |
Neer four-part fracture |
Negroid nose |
Nose finding |
Neisseria meningitidis group Z' |
Neisseria meningitidis serogroup Z (organism) |
Neisseria meningitidis serogroup D |
Neisseria meningitidis |
Neomycin sulfate 0.5% conventional release eye drops |
Product containing only neomycin in ocular dose form (medicinal product form) |
Neomycin sulfate 0.5% single-use eye drops |
Product containing only neomycin in ocular dose form (medicinal product form) |
Neomycin sulfate allergy |
Allergy to neomycin (finding) |
Neomycin+hydrocortisone 0.5%/1.5% ear drops |
Hydrocortisone 15 mg/mL and neomycin (as neomycin sulfate) 5 mg/mL ear solution |
Neonatal calf diarrhea coronavirus |
Bovine coronavirus (organism) |
Neonatal candida infection |
Neonatal candidiasis (disorder) |
Neonatal candidiasis of mouth |
Neonatal candidiasis (disorder) |
Neonatal death of female (within 4 weeks, United States of America) |
Early neonatal death |
Neonatal death of female (within 7 days, World Health Organization) |
Early neonatal death |
Neonatal death of male (within 4 weeks, United States of America) |
Early neonatal death |
Neonatal death of male (within 7 days, World Health Organization) |
Early neonatal death |
Neonatal disorder caused by toxic substance transmitted breast milk |
Neonatal disorder caused by substance transmitted via breast milk |
Neonatal hyperbilirubinemia caused by drugs and/or toxins given to the newborn |
Neonatal hyperbilirubinemia |
Neonatal intestinal perforation co-occurrent and due to congenital intestinal stenosis |
Neonatal perforation of intestine due to congenital stenosis of intestine |
Neonatal jaundice caused by drug transmitted from mother |
Neonatal disorder caused by medicinal agent transmitted via breast milk (disorder) |
Neonatal jaundice caused by toxin transmitted from mother |
Neonatal jaundice caused by substance transmitted via breast milk (finding) |
Neonatal monilia infection |
Neonatal candidiasis (disorder) |
Neonatal thrombocytopenia due to isoimmunization |
Transient neonatal thrombocytopenia |
Neophema bourkii |
Neopsephotus bourkii (organism) |
Neoplasm by body site |
Neoplastic disease |
Neoplasm of areola of female breast |
Neoplasm of areola (disorder) |